{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:19:29Z","timestamp":1788286769980,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00650"],"award-info":[{"award-number":["PI18\/00650"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PIE15\/00028"],"award-info":[{"award-number":["PIE15\/00028"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00378"],"award-info":[{"award-number":["PI15\/00378"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["EU COST Action CA 17140"],"award-info":[{"award-number":["EU COST Action CA 17140"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI17\/01246"],"award-info":[{"award-number":["FIS PI17\/01246"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0011\/0028"],"award-info":[{"award-number":["RD16\/0011\/0028"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI14\/00450"],"award-info":[{"award-number":["FIS PI14\/00450"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI15\/00272"],"award-info":[{"award-number":["FIS PI15\/00272"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Agencia Estatal de Investigaci\u00f3n (ES); Fondo Europeo de Desarrollo Regional","award":["BIO2016-76063-R"],"award-info":[{"award-number":["BIO2016-76063-R"]}]},{"DOI":"10.13039\/501100005053","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Bioingenier\u00eda, Biomateriales y Nanomedicina","doi-asserted-by":"publisher","award":["CB06\/01\/1031"],"award-info":[{"award-number":["CB06\/01\/1031"]}],"id":[{"id":"10.13039\/501100005053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005053","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Bioingenier\u00eda, Biomateriales y Nanomedicina","doi-asserted-by":"publisher","award":["4NanoMets"],"award-info":[{"award-number":["4NanoMets"]}],"id":[{"id":"10.13039\/501100005053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005053","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Bioingenier\u00eda, Biomateriales y Nanomedicina","doi-asserted-by":"publisher","award":["VENOM4CANCER"],"award-info":[{"award-number":["VENOM4CANCER"]}],"id":[{"id":"10.13039\/501100005053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017 FI_B 00680"],"award-info":[{"award-number":["2017 FI_B 00680"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017-SGR-865"],"award-info":[{"award-number":["2017-SGR-865"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017-SGR-1395"],"award-info":[{"award-number":["2017-SGR-1395"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017SGR-229"],"award-info":[{"award-number":["2017SGR-229"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005676","name":"Fundaci\u00f3n Josep Carreras Contra la Leucemia","doi-asserted-by":"publisher","award":["P\/AG"],"award-info":[{"award-number":["P\/AG"]}],"id":[{"id":"10.13039\/501100005676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008050","name":"Fundaci\u00f3n Cellex","doi-asserted-by":"publisher","award":["Grant"],"award-info":[{"award-number":["Grant"]}],"id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SLT002\/16\/00433"],"award-info":[{"award-number":["SLT002\/16\/00433"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SLT006\/17\/00093"],"award-info":[{"award-number":["SLT006\/17\/00093"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["CERCA Programme grant"],"award-info":[{"award-number":["CERCA Programme grant"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["ICREA ACADEMIA Award"],"award-info":[{"award-number":["ICREA ACADEMIA Award"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","award":["Grant"],"award-info":[{"award-number":["Grant"]}],"id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current acute myeloid leukemia (AML) therapy fails to eliminate quiescent leukemic blasts in the bone marrow, leading to about 50% of patient relapse by increasing AML burden in the bone marrow, blood, and extramedullar sites. We developed a protein-based nanoparticle conjugated to the potent antimitotic agent Auristatin E that selectively targets AML blasts because of their CXCR4 receptor overexpression (CXCR4+) as compared to normal cells. The therapeutic rationale is based on the involvement of CXCR4 overexpression in leukemic blast homing and quiescence in the bone marrow, and the association of these leukemic stem cells with minimal residual disease, dissemination, chemotherapy resistance, and lower patient survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Monomethyl Auristatin E (MMAE) was conjugated with the CXCR4 targeted protein nanoparticle T22-GFP-H6 produced in\n                      <jats:italic>E. coli<\/jats:italic>\n                      . Nanoconjugate internalization and\n                      <jats:italic>in vitro<\/jats:italic>\n                      cell viability assays were performed in CXCR4+ AML cell lines to analyze the specific antineoplastic activity through the CXCR4 receptor. In addition, a disseminated AML animal model was used to evaluate the anticancer effect of T22-GFP-H6-Auristatin in immunosuppressed NSG mice (\n                      <jats:italic>n<\/jats:italic>\n                      = 10\/group).\n                      <jats:italic>U<\/jats:italic>\n                      of Mann-Whitney test was used to consider if differences were significant between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>T22-GFP-H6-Auristatin was capable to internalize and exert antineoplastic effects through the CXCR4 receptor in THP-1 and SKM-1 CXCR4+ AML cell lines. In addition, repeated administration of the T22-GFP-H6-Auristatin nanoconjugate (9 doses daily) achieves a potent antineoplastic activity by internalizing specifically in the leukemic cells (luminescent THP-1) to selectively eliminate them. This leads to reduced involvement of leukemic cells in the bone marrow, peripheral blood, liver, and spleen, while avoiding toxicity in normal tissues in a luminescent disseminated AML mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A novel nanoconjugate for targeted drug delivery of Auristatin reduces significantly the acute myeloid leukemic cell burden in the bone marrow and blood and blocks its dissemination to extramedullar organs in a CXCR4+ AML model. This selective drug delivery approach validates CXCR4+ AML cells as a target for clinical therapy, not only promising to improve the control of leukemic dissemination but also dramatically reducing the severe toxicity of classical AML therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-020-00863-9","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T11:03:29Z","timestamp":1586948609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination"],"prefix":"10.1186","volume":"13","author":[{"given":"Victor","family":"Pallar\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugutz","family":"Unzueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u00efda","family":"Falg\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"S\u00e1nchez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naroa","family":"Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon A.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Alba-Castell\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"\u00c1lamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Villaverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isolda","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Mangues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"863_CR1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1182\/blood-2006-05-024844","volume":"109","author":"AC Spoo","year":"2007","unstructured":"Spoo AC, L\u00fcbbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786\u201391.","journal-title":"Blood."},{"key":"863_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1365-2141.2007.06590.x","volume":"137","author":"JA Burger","year":"2007","unstructured":"Burger JA, B\u00fcrkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007;137:288\u201396.","journal-title":"Br J Haematol"},{"key":"863_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.clml.2013.05.013","volume":"13","author":"S Konoplev","year":"2013","unstructured":"Konoplev S, Lin P, Yin CC, Lin E, Nogueras Gonz\u00e1lez GM, Kantarjian HM, et al. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013;13:686\u201392.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"863_CR4","doi-asserted-by":"publisher","unstructured":"Mannelli F, Cutini I, Gianfaldoni G, Bencini S, Scappini B, Pancani F, et al. CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. Cytometry B Clin Cytom. 2014. https:\/\/doi.org\/10.1002\/cytob.21156.","DOI":"10.1002\/cytob.21156"},{"key":"863_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3904\/kjim.2016.244","volume":"32","author":"B-S Cho","year":"2017","unstructured":"Cho B-S, Kim H-J, Konopleva M. Targeting the CXCL12\/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Korean J Intern Med. 2017;32:248\u201357.","journal-title":"Korean J Intern Med"},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","volume":"16","author":"K Schepers","year":"2015","unstructured":"Schepers K, Campbell TB, Passegu\u00e9 E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015;16:254\u201367.","journal-title":"Cell Stem Cell"},{"key":"863_CR7","doi-asserted-by":"publisher","first-page":"e396","DOI":"10.1038\/cddis.2012.137","volume":"3","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Patel S, Abdelouahab H, Wittner M, Willekens C, Shen S, et al. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis. 2012;3:e396.","journal-title":"Cell Death Dis"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2008-06-161539","volume":"113","author":"M Fiegl","year":"2009","unstructured":"Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, Andreeff M. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood. 2009;113:1504\u201312.","journal-title":"Blood."},{"key":"863_CR9","doi-asserted-by":"crossref","unstructured":"Fukuda S, Onishi C, Pelus LM. Trafficking of Acute Leukemia Cells \u2013 Chemokine Receptor Pathways that Modulate Leukemia Cell Dissemination. In: Antica M, editor. Acute Leukemia - The Scientist\u2019s Perspective and Challenge. InTech. 2011. p. 137\u201356.","DOI":"10.5772\/20448"},{"key":"863_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7150\/thno.21397","volume":"8","author":"S Habringer","year":"2018","unstructured":"Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, et al. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. Theranostics. 2018;8:369\u201383.","journal-title":"Theranostics."},{"key":"863_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7150\/thno.5150","volume":"3","author":"A Peled","year":"2013","unstructured":"Peled A, Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 2013;3:34\u20139.","journal-title":"Theranostics."},{"key":"863_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1582-4934.2007.00211.x","volume":"12","author":"AK Croker","year":"2008","unstructured":"Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med. 2008;12:374\u201390.","journal-title":"J Cell Mol Med"},{"key":"863_CR13","first-page":"3833","volume":"63","author":"IS Zeelenberg","year":"2003","unstructured":"Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 2003;63:3833\u20139.","journal-title":"Cancer Res"},{"key":"863_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/35065016","volume":"410","author":"A M\u00fcller","year":"2001","unstructured":"M\u00fcller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50\u20136.","journal-title":"Nature."},{"key":"863_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"1","author":"PC Hermann","year":"2007","unstructured":"Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313\u201323.","journal-title":"Cell Stem Cell"},{"key":"863_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/sj.bjc.6603251","volume":"95","author":"CC Schimanski","year":"2006","unstructured":"Schimanski CC, Bahre R, Gockel I, M\u00fcller A, Frerichs K, H\u00f6rner V, et al. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer. 2006;95:210\u20137.","journal-title":"Br J Cancer"},{"key":"863_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1741-7015-10-85","volume":"10","author":"S Zhang","year":"2012","unstructured":"Zhang S, Han Z, Jing Y, Tao S, Li T, Wang H, et al. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med. 2012;10:85.","journal-title":"BMC Med"},{"key":"863_CR18","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1038\/s41598-017-07848-8","volume":"7","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Saavedra E, Tang R, Gu Y, Lappin P, Trajkovic D, et al. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143). Sci Rep. 2017;7:7305.","journal-title":"Sci Rep"},{"key":"863_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/17425240902780166","volume":"6","author":"M Das","year":"2009","unstructured":"Das M, Mohanty C, Sahoo SK. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv. 2009;6:285\u2013304.","journal-title":"Expert Opin Drug Deliv"},{"key":"863_CR20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3324\/haematol.2013.085209","volume":"99","author":"DA Pollyea","year":"2014","unstructured":"Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014;99:1277\u201384.","journal-title":"Haematologica."},{"key":"863_CR21","first-page":"4533","volume":"7","author":"U Unzueta","year":"2012","unstructured":"Unzueta U, C\u00e9spedes MV, Ferrer-Miralles N, Casanova I, Cedano J, Corchero JL, et al. Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine. 2012;7:4533\u201344.","journal-title":"Int J Nanomedicine"},{"key":"863_CR22","doi-asserted-by":"crossref","unstructured":"C\u00e9spedes MV, Unzueta U, Avi\u00f1\u00f3 A, Gallardo A, \u00c1lamo P, Sala R, et al. Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO Mol Med. 2018;10.","DOI":"10.15252\/emmm.201708772"},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1016\/j.bmc.2014.02.035","volume":"22","author":"JJ Field","year":"2014","unstructured":"Field JJ, Kanakkanthara A, Miller JH. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorg Med Chem. 2014;22:5050\u20139.","journal-title":"Bioorg Med Chem"},{"key":"863_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/bcp.13126","volume":"83","author":"D Bates","year":"2017","unstructured":"Bates D, Eastman A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol. 2017;83:255\u201368.","journal-title":"Br J Clin Pharmacol"},{"key":"863_CR25","volume-title":"ImageJ2: ImageJ for the next generation of scientific image data","author":"CT Rueden","year":"2017","unstructured":"Rueden CT. ImageJ2: ImageJ for the next generation of scientific image data; 2017."},{"key":"863_CR26","doi-asserted-by":"publisher","unstructured":"Falg\u00e0s A, Pallar\u00e8s V, Unzueta U, C\u00e9spedes MV, Arroyo-Solera I, Moreno MJ, et al. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2018.211490.","DOI":"10.3324\/haematol.2018.211490"},{"key":"863_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/1078-0432.CCR-12-2333","volume":"19","author":"MR Kuhne","year":"2013","unstructured":"Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, et al. BMS-936564\/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19:357\u201366.","journal-title":"Clin Cancer Res"},{"key":"863_CR28","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/cas.13263","volume":"108","author":"C Xie","year":"2017","unstructured":"Xie C, He Y, Zhen M, Wang Y, Xu Y, Lou L. Puquitinib, a novel orally available PI3K\u03b4 inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia. Cancer Sci. 2017;108:1476\u201384.","journal-title":"Cancer Sci"},{"key":"863_CR29","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.molonc.2015.05.005","volume":"9","author":"G Srivastava","year":"2015","unstructured":"Srivastava G, Matta A, Fu G, Somasundaram RT, Datti A, Walfish PG, et al. Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy. Mol Oncol. 2015;9:1720\u201335.","journal-title":"Mol Oncol"},{"key":"863_CR30","doi-asserted-by":"publisher","first-page":"e83160","DOI":"10.1371\/journal.pone.0083160","volume":"9","author":"W-H Lin","year":"2014","unstructured":"Lin W-H, Yeh T-K, Jiaang W-T, Yen K-J, Chen C-H, Huang C-T, et al. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer. PLoS One. 2014;9:e83160.","journal-title":"PLoS One"},{"key":"863_CR31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1208\/s12248-013-9480-8","volume":"15","author":"GJ Fetterly","year":"2013","unstructured":"Fetterly GJ, Aras U, Lal D, Murphy M, Meholick PD, Wang ES. Development of a preclinical PK\/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia. AAPS J. 2013;15:662\u201373.","journal-title":"AAPS J"},{"key":"863_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-016-0280-3","volume":"9","author":"C Lehmann","year":"2016","unstructured":"Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. J Hematol Oncol. 2016;9:50.","journal-title":"J Hematol Oncol"},{"key":"863_CR33","doi-asserted-by":"publisher","unstructured":"Christian S, Merz C, Evans L, Gradl S, Seidel H, Friberg A, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019. https:\/\/doi.org\/10.1038\/s41375-019-0461-5.","DOI":"10.1038\/s41375-019-0461-5"},{"key":"863_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","volume":"17","author":"F Li","year":"2018","unstructured":"Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, et al. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia. Mol Cancer Ther. 2018;17:554\u201364.","journal-title":"Mol Cancer Ther"},{"key":"863_CR35","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341.","journal-title":"Nat Commun"},{"key":"863_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4252\/wjsc.v10.i6.57","volume":"10","author":"C Mambet","year":"2018","unstructured":"Mambet C, Chivu-Economescu M, Matei L, Necula LG, Dragu DL, Bleotu C, et al. Murine models based on acute myeloid leukemia-initiating stem cells xenografting. World J Stem Cells. 2018;10:57\u201365.","journal-title":"World J Stem Cells"},{"key":"863_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","volume":"29","author":"MY Konopleva","year":"2011","unstructured":"Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591\u20139.","journal-title":"J Clin Oncol"},{"key":"863_CR38","doi-asserted-by":"crossref","unstructured":"Centelles JJ. Treatment of Acute Myeloid Leukemia. Curr Synthetic Sys Biol. 2014;02.","DOI":"10.4172\/2332-0737.1000114"},{"key":"863_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40265-013-0031-5","volume":"73","author":"KP Garnock-Jones","year":"2013","unstructured":"Garnock-Jones KP. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs. 2013;73:371\u201381.","journal-title":"Drugs."},{"key":"863_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12964-017-0163-4","volume":"15","author":"F Aberger","year":"2017","unstructured":"Aberger F, Hutterer E, Sternberg C, Del Burgo PJ, Hartmann TN. Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog\/GLI signaling. Cell Commun Signal. 2017;15:8.","journal-title":"Cell Commun Signal"},{"key":"863_CR41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/cas.12655","volume":"106","author":"E Ashihara","year":"2015","unstructured":"Ashihara E, Takada T, Maekawa T. Targeting the canonical Wnt\/\u03b2-catenin pathway in hematological malignancies. Cancer Sci. 2015;106:665\u201371.","journal-title":"Cancer Sci"},{"key":"863_CR42","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1021\/acs.molpharmaceut.5b00302","volume":"12","author":"JM Lambert","year":"2015","unstructured":"Lambert JM. Antibody-Drug Conjugates (ADCs): Magic Bullets at Last! Mol Pharm. 2015;12:1701\u20132.","journal-title":"Mol Pharm"},{"key":"863_CR43","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.nano.2016.04.003","volume":"12","author":"MV C\u00e9spedes","year":"2016","unstructured":"C\u00e9spedes MV, Unzueta U, \u00c1lamo P, Gallardo A, Sala R, Casanova I, et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models. Nanomedicine. 2016;12:1987\u201396.","journal-title":"Nanomedicine."},{"key":"863_CR44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/PAI.0b013e3182606f4d","volume":"21","author":"JY Ahn","year":"2013","unstructured":"Ahn JY, Seo K, Weinberg OK, Arber DA. The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol. 2013;21:79\u201384.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"863_CR45","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/cncr.22510","volume":"109","author":"S Konoplev","year":"2007","unstructured":"Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007;109:1152\u20136.","journal-title":"Cancer."},{"key":"863_CR46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/blood-2004-02-0566","volume":"104","author":"EJC Rombouts","year":"2004","unstructured":"Rombouts EJC, Pavic B, L\u00f6wenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004;104:550\u20137.","journal-title":"Blood."},{"key":"863_CR47","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1158\/0008-5472.CAN-03-3693","volume":"64","author":"S Tavor","year":"2004","unstructured":"Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD\/SCID mice. Cancer Res. 2004;64:2817\u201324.","journal-title":"Cancer Res"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00863-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00863-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00863-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T20:23:59Z","timestamp":1618431839000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00863-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00863-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"4 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed on animals were conducted in accordance with the guidelines approved by the institutional animal Ethics Committee of Hospital Sant Pau.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EV, RM, and AV are co-founders of Nanoligent, a company devoted to develop anticancer drugs based on proteins.UU, EV, AV, RM, and IC are cited as inventors in a patent application (EP11382005.4) covering the therapeutic use of T22. All other authors report no conflicts of interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}